Table 5.

Linear regression model predicting eGFR changes (in milliliters per minute) in patients with stage 3 CKD (n=56) over the study period

Predictors of eGFR Changes	Univariate Model		Multivariable Model
	β (95% CI)	P Value	β (95% CI)	P Value
Age, per 10 yr	−0.06 (−2.8 to 2.7)	0.97	0.81 (−1.9 to 3.5)	0.56
Sex, men versus women	1.6 (−4.2 to 7.4)	0.58	−0.27 (−6.2 to 5.6)	0.93
Race, white versus nonwhite	2.6 (−2.6 to 7.9)	0.32	0.54 (−4.7 to 5.8)	0.84
Diabetes versus nondiabetic	−6.9 (−11 to −2.1)	<0.01	−8.0 (−13 to −2.7)	0.004
Cirrhosis versus noncirrhotic	−1.1 (−6.4 to 4.3)	0.69	−0.74 (−6.3 to 4.8)	0.79
Hypertension versus normotensive	−3.9 (−11 to 3.3)	0.29	−3.3 (−10.7 to 4.1)	0.37
Baseline eGFR, per 10-ml/min increase in eGFR	−0.05 (−3.1 to 3.0)	0.97	−1.5 (−4.8 to 1.7)	0.34
Achieving sustained virologic response	6.4 (−2.5 to 15.2)	0.15	9.3 (0.44 to 18)	0.04

Model constructed to predict change in eGFR in milliliters per minute from baseline to 6-month follow-up period. Post-treatment follow-up eGFR is missing from n=2 patients with baseline eGFR ≥60 ml/min per 1.73 m² and n=1 patient with baseline eGFR <60 ml/min per 1.73 m². 95% CI, 95% confidence interval.